📰 Dan Budwick News
Page 2 - Dan Budwick News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dan Budwick. Real-time updates on events, politics, business and more.
April 1, 2024
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer in the...
April 1, 2024
EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to dev...
March 28, 2024
Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and...
March 26, 2024
Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024CAMBRIDGE, Mass., March 26, 2024 -- Beam Therapeutics Inc. , a biotechnology company developing precision genetic...
March 26, 2024
CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the clearance of its clinical
March 25, 2024
Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing...
March 13, 2024
SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of
February 28, 2024
CAMBRIDGE, Mass., Feb. 28, 2024 -- Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in...
February 28, 2024
CAMBRIDGE, Mass., Feb. 28, 2024 -- Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that...
February 28, 2024
WALTHAM, Mass., Feb. 28, 2024 -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with...